Business
Arius announces issuance of two U.S. patents
Arius announces issuance of two U.S. patents.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\nTORONTO, Aug. 14 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology\ncompany discovering and developing the next wave of antibody therapeutics,\ntoday announced that the Company has been granted two U.S. patents for\nantibodies; one patent within the CD63 Program, which has been licensed to the\nCompany's partner Genentech, Inc. and a second patent within the\ncarcinoembryonic antigen (CEA) Program.\n\n\nU.S. Patent 7,256,272 covers composition of matter claims for a CD63\ntargeting antibody and clone. The CD63 targeting antibody has the potential to\nrecruit the body's own defense system to attack cancer and has been shown to\nprevent tumor growth and enhance survival in breast cancer models.\n\n\nU.S. Patent 7,256,271 contains claims on a targeting antibody and clone\ncomposition of matter. CEA is a broadly expressed tumor marker and ARIUS' CEA\ntargeting antibody has demonstrated potent anti-tumour activity in colon and\nbreast cancer models.\n\n\nAbout ARIUS\n\n\nARIUS is a biotechnology company discovering and developing the next wave\nof antibody therapeutics. Established in 1999, ARIUS has built a proprietary\ntechnology platform, FunctionFIRST(TM), that rapidly identifies and selects\nantibodies based on their functional ability to affect disease. This antibody\ngeneration engine has enabled ARIUS to assemble a portfolio of more than 400\nantibody candidates. In addition to the antibodies it is developing in-house,\nARIUS has ongoing partnerships with key biotechnology and drug development\ncompanies. ARIUS is listed on the TSX under the symbol "ARI". For further\ninformation, visit www.ariusresearch.com\n\n\nForward-Looking Statements\n\n\nCertain statements in this news release constitute "forward-looking\nstatements" within the meaning of the Private Securities Litigation Reform Act\nof 1995, which involve known and unknown risks, uncertainties and other\nfactors that may cause our actual results to be materially different from any\nfuture results, performance or achievements expressed or implied by such\nstatements. Forward-looking statements in this release include, but are not\nlimited to, ARIUS successfully advancing its new product programs as well as\nlicensing opportunities. These statements are only predictions and actual\nevents or results may differ materially. Factors that ...